The Alyra intrauterine device – contains ~37mg of levonorgestrel releasing approximately 9.6 micrograms per 24 hours and ~27 mg of amitriptyline releasing approximately 0.35 mg per 24 hours. The device will be inserted by a specialist Gynaecologist highly experienced in the placement of IUDs in the general population. The Alyra intrauterine device is placed in exactly the same way, and by the same procedures and practices, as that with a standard Mirena 'Trademark' device. Only study approved Gy
Sponsors
Alyra Biotech Pty Ltd
Phase 1
The Womens wellness through Intrauterine Neuroimmune modulation study: The effect of a new intrauterine device on pelvic pain in women.
CompletedACTRN12623000675628
Start: 2023-12-18End: 2024-04-17Target: 12Updated: 2025-01-06
The womens Wellness Intrauterine Neuroimmune modulation Study Expansion Group: The effect of a new intrauterine device on pelvic pain in women.
RecruitingACTRN12624001286538
Start: 2024-12-20End: 2025-06-30Target: 90Updated: 2025-09-08